Trial Profile
A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO 6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs CNTO 6785 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 01 Nov 2017 Primary endpoint (The proportion of participants who achieve an ACR 20 response at Week 16) has not been met, according to results published in The Journal of Rheumatology.
- 01 Nov 2017 Results published in The Journal of Rheumatology.
- 23 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.